by Jakub Jarolím, Business Intelligence Department
Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).
SOTIO Biotech
13/3/2023
February 2023 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions
Market
Current uncertainty and economic challenges bring opportunities to well-funded companies
Interest rates, competitive labor and increasing biosimilar competition will be the challenges in 2023. With these challenges and uncertainty come numerous opportunities for companies that are well capitalized. Biotech went through its IPO boom and now shakeout is underway.
Antibody-Drug Conjugates
Magenta to explore strategic alternatives after patient’s death in Phase 1/2
A week after pausing enrollment in a Phase 1/2 study of targeted conditioning agent MGTA-117 due to the death of a patient, Magenta Therapeutics is now seeking strategic alternatives and stopping development of all programs.
Interleukin-15 and Interleukin-2
ImmunityBio presented favorable QOL data from its Phase 2/3 trial in bladder cancer
ImmunityBio presented "Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer receiving IL-15R⍺Fc superagonist N-803 plus BCG" at the ASCO GU conference in San Francisco.
Other Innovative Treatment Areas
GSK’s Jemperli granted full approval to treat endometrial cancer
FDA granted full approval to Jemperli dostarlimab-gxly from GSK to treat patients with mismatch repair deficient recurrent or advanced endometrial cancer.
Sdílet na sociálních sítích